IL2 and metastatic melanoma: Approved treatments for metastatic melanoma include high-dose interleukin-2 (IL-2) and chemotherapy [6], [7], which have, at best, an overall response rate of 16% and 7.5%, with very few complete responders and almost no long-term survivors [7].